Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This is Phase II trial of nivolumab plus axitinib for patients with unresectable stage III or
IV melanoma who have progressed on prior anti-PD1 therapy with or without concomitant
anti-CTLA4 therapy. Patients will receive treatment with nivolumab 480 mg intravenously every
4 weeks and axitinib 5 mg twice daily by mouth. Patients may continue both agents for up to
two years if they do not experience disease progression or dose-limiting toxicities.